Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29298

1.

Antibody Arrays in Biomarker Discovery.

Wilson JJ, Burgess R, Mao YQ, Luo S, Tang H, Jones VS, Weisheng B, Huang RY, Chen X, Huang RP.

Adv Clin Chem. 2015;69:255-324. doi: 10.1016/bs.acc.2015.01.002. Epub 2015 Feb 26.

PMID:
25934364
2.

Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.

Liu J, Liu B, Guo G, Jing Y, Zhao G.

Anticancer Drugs. 2015 Apr 29. [Epub ahead of print]

PMID:
25933245
3.

Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer.

Miyoshi Y, Noguchi K, Yanagisawa M, Taguri M, Morita S, Ikeda I, Fujinami K, Miura T, Kobayashi K, Uemura H.

BMC Cancer. 2015 May 1;15(1):338. [Epub ahead of print]

PMID:
25929438
4.
5.

Carotenoid Profile of Tomato Sauces: Effect of Cooking Time and Content of Extra Virgin Olive Oil.

Vallverdú-Queralt A, Regueiro J, de Alvarenga JF, Torrado X, Lamuela-Raventos RM.

Int J Mol Sci. 2015 Apr 28;16(5):9588-9599.

6.

In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles.

Zhu Y, Sun Y, Chen Y, Liu W, Jiang J, Guan W, Zhang Z, Duan Y.

Int J Mol Sci. 2015 Apr 28;16(5):9573-9587.

7.

Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.

Hu CD, Choo R, Huang J.

Front Oncol. 2015 Apr 14;5:90. doi: 10.3389/fonc.2015.00090. eCollection 2015. Review.

8.

Production and Characterization of Monoclonal Antibodies against Human Prostate Specific Antigen.

Bayat AA, Ghods R, Shabani M, Mahmoudi AR, Yeganeh O, Hassannia H, Sadeghitabar A, Balay-Goli L, Noutash-Haghighat F, Sarrafzadeh AR, Jeddi-Tehrani M.

Avicenna J Med Biotechnol. 2015 Jan-Mar;7(1):2-7.

PMID:
25926946
9.

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml<sup>-1</sup>.

Chen R, Zhou LQ, Cai XB, Xie LP, Huang YR, He DL, Gao X, Xu CL, Ding Q, Wei Q, Yin CJ, Ren SC, Wang FB, Tian Y, Sun ZQ, Fu Q, Ma LL, Zheng JH, Ye ZQ, Ye DW, Xu DF, Hou JQ, Xu KX, Yuan JL, Gao X, Liu CX, Pan TJ, Sun YH; Chinese Prostate Cancer Consortium.

Asian J Androl. 2015 Apr 24. doi: 10.4103/1008-682X.150846. [Epub ahead of print]

PMID:
25926603
10.

Novel prostate cancer biomarkers derived from autoantibody signatures.

Schipper M, Wang G, Giles N, Ohrnberger J.

Transl Oncol. 2015 Apr;8(2):106-11. doi: 10.1016/j.tranon.2015.02.003.

11.

Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate CAncer (THEPCA) Patients and Its Effects on Toxicity and Quality of Life: Protocol of a Randomized Feasibility Trial.

Palvai S, Harrison M, Shibu Thomas S, Hayden K, Green J, Anderson O, Romero L, Lodge R, Burns P, Ahmed I.

JMIR Res Protoc. 2015 Apr 29;4(2):e49. doi: 10.2196/resprot.4462.

12.

Selenium, nickel, and calcium levels in cancerous and non-cancerous prostate tissue samples and their relation with some parameters.

Çelen İ, Müezzinoğlu T, Ataman OY, Bakırdere S, Korkmaz M, Neşe N, Şenol F, Lekili M.

Environ Sci Pollut Res Int. 2015 Apr 30. [Epub ahead of print]

PMID:
25925146
13.

Anterior apical cores in the initial prostate biopsy does not increase detection of significant prostate cancer.

Ekin RG, Zorlu F, Akarken I, Yildirim Z, Tarhan H, Koc G, Kucuk U, Bayol U.

Urol J. 2015 Apr 29;12(2):2084-9.

14.

Challenging the Inevitability of Prostate Enlargement: Low Levels of Benign Prostatic Hyperplasia Among Tsimane Forager-Horticulturalists.

Trumble BC, Stieglitz J, Rodriguez DE, Linares EC, Kaplan HS, Gurven MD.

J Gerontol A Biol Sci Med Sci. 2015 Apr 28. pii: glv051. [Epub ahead of print]

PMID:
25922348
15.

Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.

Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM.

Eur Urol. 2015 Apr 25. pii: S0302-2838(15)00318-8. doi: 10.1016/j.eururo.2015.04.016. [Epub ahead of print]

PMID:
25922274
16.

TESTOSTERONE REPLACEMENT THERAPY IN OLDER MALE SUBJECTIVE MEMORY COMPLAINERS : DOUBLE-BLIND RANDOMIZED CROSSOVER PLACEBO-CONTROLLED CLINICAL TRIAL OF PHYSIOLOGICAL ASSESSMENT AND SAFETY.

Asih PR, Wahjoepramono EJ, Aniwiyanti V, Wijaya LK, Ruyck K, Taddei K, Fuller SJ, Sohrabi H, Dhaliwal SS, Verdile G, Carruthers M, Martins RN.

CNS Neurol Disord Drug Targets. 2015 Apr 29. [Epub ahead of print]

PMID:
25921747
17.
18.

Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Bianco V, Ponchietti R, Barbanti G, Francini E.

Clin Genitourin Cancer. 2015 Mar 26. pii: S1558-7673(15)00069-5. doi: 10.1016/j.clgc.2015.03.004. [Epub ahead of print]

PMID:
25920994
19.

Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP.

Steck SE, Arab L, Zhang H, Bensen JT, Fontham ET, Johnson CS, Mohler JL, Smith GJ, Su JL, Trump DL, Woloszynska-Read A.

PLoS One. 2015 Apr 28;10(4):e0125151. doi: 10.1371/journal.pone.0125151. eCollection 2015.

20.

Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer.

Peskoe SB, Joshu CE, Rohrmann S, McGlynn KA, Nyante SJ, Bradwin G, Dobs AS, Kanarek N, Nelson WG, Platz EA.

Prostate. 2015 Apr 28. doi: 10.1002/pros.22998. [Epub ahead of print]

PMID:
25919471
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk